Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib for Ibrutinib-Resistant CLL/SLL
NCT04209621Phase 2Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Overall Response Rate at 12 weeks. Started Jul 2020; status: terminated.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04209621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209621.